Article

Histology-Derived Signatures Predict Recurrence Risk and Chemotherapy Benefit in Randomized Trials of Early Breast Cancer

2026-04-24

Abstract excerpt

<h4>Purpose</h4> To test whether histology-derived gene-expression signatures from routine hematoxylin and eosin slides are prognostic for recurrence and predictive of chemotherapy benefit in early breast cancer. <h4>Methods</h4> We conducted a multi-cohort study including CALGB 9344 (anthracycline ± paclitaxel), CALGB 9741 (standard vs dose-dense chemotherapy), a pooled Chicago real-world cohort, and the Americ...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 53ec9e18-5280-521f-a81a-35653b876adc
DOI: 10.64898/2026.04.23.26351499

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Histology-Derived Signatures Predict Recurrence Risk and Chemotherapy Benefit in Randomized Trials of Early Breast CancerDOI 10.64898/2026.04.23.26351499Read

Development and Validation of a Multimodal Clinical, Pathologic, and Genomic Model for Breast Cancer RecurrenceSemantic proximity Read

Clinical Validation of RlapsRisk BC in an international multi-cohorts settingSemantic proximity Read

Multimodal histopathologic models stratify hormone receptor-positive early breast cancerSemantic proximity Read

Integration of Gene Expression and Digital Histology to Predict Treatment-Specific Responses in Breast CancerSemantic proximity Read

Deep Learning on Histopathological Images to Predict Breast Cancer Recurrence Risk and Chemotherapy BenefitSemantic proximity Read

Deep learning from HE slides to predict the clinical benefit from adjuvant chemotherapy in hormone receptor-positive breast cancerSemantic proximity Read

High concordance of 70-gene recurrence risk signature and 80-gene molecular subtyping signature between core needle biopsy and surgical resection specimens in early-stage breast cancerSemantic proximity Read

Genomic Machine Learning Model Predicts Radiation Therapy Benefit in Early-Stage Breast Cancer Patients with High AccuracySemantic proximity Read

Estimated survival outcomes and absolute chemotherapy treatment benefit using PREDICT Tool® and EndoPredict®, in hormone-positive early-stage breast cancer.Semantic proximity Read

Multimodal Prediction of Breast Cancer Recurrence Assays and Risk of RecurrenceSemantic proximity Read

Assessing the risk of recurrence in early-stage breast cancer through H&E stained whole slide imagesSemantic proximity Read

PreciseBreast is prognostic for breast cancer recurrence in a 21-gene assay managed cohortSemantic proximity Read